Liberizin (Cytisinicline)

Liberizin, a partial agonist of nicotinic acetylcholine receptors, is used in the management of nicotine dependence.

• Smoking cessation: helps reduce cravings and withdrawal symptoms in adults attempting to quit tobacco use.
• Nicotine withdrawal: alleviates common discomforts such as irritability and anxiety during cessation.
• Tobacco dependence: supports gradual reduction of nicotine intake as part of a comprehensive quit plan.

• Cytisinicline binds to the α4β2 subtype of nicotinic acetylcholine receptors in the central nervous system, acting as a partial agonist. This activity produces modest receptor stimulation that mitigates the surge of dopamine associated with nicotine intake, thereby reducing withdrawal symptoms and cravings while allowing the receptor to remain responsive to endogenous acetylcholine.

Adverse reactions may occur with Liberizin and are categorized by frequency.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Headache: transient tension‑type pain.
• Insomnia: difficulty falling or staying asleep.
• Vivid dreams: unusually intense or memorable dreams.
• Dizziness: light‑headed sensation, especially when standing quickly.
• Dry mouth: reduced salivation.

Serious or Rare Side Effects

• Mood changes: depression, anxiety, or suicidal thoughts.
• Seizures: rare convulsive episodes.
• Severe allergic reaction: rash, swelling, or difficulty breathing.
• Cardiovascular events: chest pain or arrhythmia.
• Psychotic symptoms: hallucinations or delusional thinking.

Before initiating Liberizin, several safety considerations should be reviewed.

• Cardiovascular assessment: evaluate history of heart disease before use.
• Neuropsychiatric monitoring: watch for mood swings, depression, or suicidal ideation.
• Liver function: check hepatic enzymes in patients with liver impairment.
• Concomitant smoking: advise patients not to resume smoking while on therapy.
• Psychiatric history: use with caution in individuals with prior mental health disorders.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Cytisinicline may interact with other medicines; interactions are grouped by clinical significance.

Major Interactions (Avoid)

• Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis.
• Other nicotinic agonists (e.g., varenicline): additive stimulation of receptors.
• Strong CYP2A6 inhibitors: may increase Cytisinicline plasma levels.

Moderate Interactions (Monitor Closely)

• CYP2B6 substrates (e.g., bupropion): potential altered metabolism.
• Antihypertensive agents: possible blood pressure changes.
• Alcohol: may enhance central nervous system effects.
• Caffeine: could increase nervous system stimulation.